Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Hashimoto

Showing results (11-20 of 861) with videos related to

Pageof 87
Sort By:
Cancers|June 2, 2021
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug DevelopmentKenji Hashimoto
Expert Opinion on Therapeutic Targets|June 27, 2014
Targeting of NMDA receptors in new treatments for schizophreniaKenji Hashimoto
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|January 18, 2007
BDNF variant linked to anxiety-related behaviorsKenji Hashimoto
Biochemical Pharmacology|April 1, 2020
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamineKenji Hashimoto
Psychopharmacology|September 6, 2014
Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamineKenji Hashimoto
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 19, 2017
[Biomarkers for Mood Disorders and a Novel Antidepressant (R)-ketamine]Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|June 9, 2017
Abnormalities in the brain-immune system in psychotic disorders: from pathogenesis to preventionKenji Hashimoto
Expert Opinion on Therapeutic Targets|September 21, 2016
Ketamine's antidepressant action: beyond NMDA receptor inhibitionKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|June 28, 2018
Biomarkers for Alzheimer's disease: from pathogenesis to drug developmentKenji Hashimoto
Journal of Pharmacological Sciences|February 24, 2015
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implicationKenji Hashimoto
Pageof 87

Showing results (11-20 of 861) with videos related to

Sort By:
Pageof 87
Cancers|June 2, 2021
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug DevelopmentKenji Hashimoto
Expert Opinion on Therapeutic Targets|June 27, 2014
Targeting of NMDA receptors in new treatments for schizophreniaKenji Hashimoto
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|January 18, 2007
BDNF variant linked to anxiety-related behaviorsKenji Hashimoto
Biochemical Pharmacology|April 1, 2020
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamineKenji Hashimoto
Psychopharmacology|September 6, 2014
Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamineKenji Hashimoto
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 19, 2017
[Biomarkers for Mood Disorders and a Novel Antidepressant (R)-ketamine]Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|June 9, 2017
Abnormalities in the brain-immune system in psychotic disorders: from pathogenesis to preventionKenji Hashimoto
Expert Opinion on Therapeutic Targets|September 21, 2016
Ketamine's antidepressant action: beyond NMDA receptor inhibitionKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|June 28, 2018
Biomarkers for Alzheimer's disease: from pathogenesis to drug developmentKenji Hashimoto
Journal of Pharmacological Sciences|February 24, 2015
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implicationKenji Hashimoto
Pageof 87